Growing healthcare demand driven by population aging and advances in medical care
First written in FY2016. 10 of 11 entries say "Restated". Latest entry: FY2019-Q3.
The whole theme swung hardest in 2021: 1 of 10 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
- FY2019-Q3RestatedAnnual report
「Various healthcare system reforms are also being implemented in the contract clinical testing industry to contain ever-increasing national healthcare expenditure.」
Continues to identify rising national healthcare expenditure and healthcare system reforms to contain it as business conditions. - FY2019-Q2RestatedAnnual report
「Various healthcare system reforms are also being implemented in the contract clinical testing industry to contain ever-increasing national healthcare expenditure.」
Continues to identify rising national healthcare expenditure and healthcare system reforms to contain it as business conditions. - FY2019-Q1RestatedAnnual report
「Various healthcare system reforms are also being implemented in the contract clinical testing industry to contain ever-increasing national healthcare expenditure.」
Continues to identify rising national healthcare expenditure and healthcare system reforms to contain it as business conditions. - FY2018-Q3RestatedAnnual report
「National healthcare expenditure has been trending upward each year amid population aging, the spread of high-priced drugs and advances in medical technology, and is expected to accelerate further. As a result, various healthcare system reforms have been implemented and a range of initiatives have been undertaken to contain medical costs.」
Continues to identify rising national healthcare expenditure driven by population aging, the spread of high-priced drugs and advances in medical technology, along with measures to contain medical costs, as business conditions. - FY2018-Q2RestatedAnnual report
「National healthcare expenditure has been trending upward each year amid population aging, the spread of high-priced drugs and advances in medical technology, and is expected to accelerate further. As a result, various healthcare system reforms have been implemented and a range of initiatives have been undertaken to contain medical costs.」
Continues to identify rising national healthcare expenditure driven by population aging, the spread of high-priced drugs and advances in medical technology, along with measures to contain medical costs, as business conditions. - FY2018-Q1RestatedAnnual report
「National healthcare expenditure has continued to increase by several hundred billion yen each year amid population aging, the spread of high-priced drugs and advances in healthcare, and is expected to accelerate further. As a result, various healthcare system reforms have been implemented and a range of initiatives have been undertaken to contain medical costs.」
Continues to identify rising national healthcare expenditure driven by population aging, advances in healthcare and the spread of high-priced drugs, along with measures to contain medical costs, as business conditions. - FY2017RestatedAnnual report
「In Japan, national medical expenditure has reached a record high against a backdrop of rapidly advancing population aging and increasingly sophisticated medical care, and is expected to continue rising. As a result, various healthcare system reforms have been implemented and a range of measures have been taken to contain medical expenditure.」
Continues to identify rising medical costs due to population aging and advances in healthcare, along with institutional reforms aimed at containing medical costs, as business conditions. - FY2017-Q3RestatedAnnual report
「In Japan, national medical expenditure has reached a record high against a backdrop of rapidly advancing population aging and increasingly sophisticated medical care, and is expected to continue rising. As a result, various healthcare system reforms have been implemented and a range of measures have been taken to contain medical expenditure.」
Continues to identify rising medical costs due to population aging and advances in healthcare, along with measures to contain medical costs, as business conditions. - FY2017-Q2RestatedAnnual report
「In Japan, national medical expenditure has reached a record high against a backdrop of rapidly advancing population aging and increasingly sophisticated medical care, and is expected to continue rising. As a result, various healthcare system reforms have been implemented and a range of measures have been taken to contain medical expenditure.」
Continues to identify rising medical costs due to population aging and advances in healthcare, along with measures to contain medical costs, as business conditions. - FY2017-Q1RestatedAnnual report
「In Japan, national medical expenditure has reached a record high against a backdrop of rapidly advancing population aging and increasingly sophisticated medical care, and is expected to continue rising. As a result, various healthcare system reforms have been implemented and a range of measures have been taken to contain medical expenditure.」
The Company continues to describe rising medical expenditure driven by population aging and advances in medical care, together with efforts to contain medical expenditure, as part of its business environment. - FY2016First statedAnnual report
「In Japan, national medical expenditure has reached a record high against a backdrop of rapidly advancing population aging and increasingly sophisticated medical care, and is expected to continue rising.」
The Company describes the increase in national medical expenditure driven by population aging and advances in medical care as a structural fact shaping its business environment.